Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Bio-Rad Introduces New Bio-Plex Pro™ RBM Kidney Toxicity Panels

Published: Thursday, March 14, 2013
Last Updated: Thursday, March 14, 2013
Bookmark and Share
The Bio-Plex Pro™ RBM human, rat, and canine kidney toxicity panels enable early detection and characterization of kidney toxicity and injury during drug development.

Bio-Rad Laboratories, Inc. has announced the launch of its new Bio-Plex Pro RBM human, rat, and canine kidney toxicity panels at the 2013 Society of Toxicology (SOT) annual meeting in San Antonio, TX, March 10-14.

Developed through a partnership with Myriad RBM, Inc., the multiplex immunoassays comprise a set of biomarkers that addresses the need for early detection and characterization of kidney toxicity and injury during drug development.

Acute kidney injury (AKI) is a potentially deadly condition frequently caused by kidney damage due to drug exposure, trauma, or blood loss during a medical procedure.

In contrast, chronic kidney injury (CKI) results from long-term diseases such as diabetes, high blood pressure, or an inherited syndrome.

Protein biomarkers found in urine can signal early signs of kidney toxicity and injury and may provide additional information about the location and severity of damage.

The Bio-Plex Pro RBM assays enable the detection of multiple biomarkers in a single sample, which may reveal damage within hours of kidney injury.

This early detection will allow for more efficient drug testing in both preclinical and clinical research settings.

“The decades-old current clinical tests are not able to detect damage early enough, as evidenced by the fact that two-thirds of the kidney may be irreparably damaged once the traditional biomarkers become elevated,” said Dr. Dominic Eisinger, director of strategic development for Myriad RBM.

Dr. Eisinger continued, “The Bio-Plex Pro RBM panels encompass the most sensitive early markers of kidney injury for preclinical and clinical studies.”

The toxicity panels contain six of the seven markers approved by the FDA and EMEA for use in preclinical kidney toxicity assessment.

Included in these panels are several other markers relevant to kidney toxicity and damage research. The assays are offered as kits that include everything needed to run the assay.

“The Bio-Plex Pro RBM kidney toxicity assays will allow preclinical researchers to monitor biomarker profiles that may predict drug toxicity in the clinic,” said Chris Linnevers, Bio-Rad’s Bio-Plex global product manager.

Linnevers continued, “They also enable clinical researchers to monitor both disease progression and kidney injury during drug trials, which ultimately leads to better-optimized treatment and improved patient care.”

Dr. Eisinger will give a talk on the new assays at the SOT annual meeting. His talk, “Multiplex detection of drug-induced kidney toxicity with new Bio-Plex Pro RBM assays,” will review the need for sensitive and robust assays to evaluate and diagnose kidney injury.

Investigators involved in preclinical and clinical studies of drug safety will learn about the analytical validation of the kits, including their performance in kidney injury studies.

Additional benefits of the Bio-Plex Pro RBM assays include:
• High performance - offer robust quantification of multiple proteins in human, rat, and canine urine samples
• Consistent results - optimized for high precision and lot-to-lot reproducibility of sample measurements
• Simple workflow - formatted on magnetic beads for simplified plate processing and rapid results

The Bio-Plex Pro RBM kidney toxicity panels are compatible with Bio-Plex® MAGPIX™ instruments and Bio-Plex 100/200 and 3D instruments as well as all Luminex platforms and software.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bio-Rad and Myriad RBM Partner to Develop Immunoassay Kits
Partnership to commercialize multiplex biomarker kits for life science research.
Wednesday, August 01, 2012
Bio-Rad Announces Web Seminar Series
Bio-Rad's second series of web seminars beginning in August will focus on the latest approaches in metabolomics, spectroscopy and ADME/Tox.
Thursday, July 20, 2006
Bio-Rad Announces Web Seminar Series
Web seminar series area includes Spectroscopy, Chromatography, ADME/Tox and Metabolomics.
Friday, May 05, 2006
Bio-Rad Receives Frost & Sullivan's 2005 Product Innovation Award
Bio-Rad's KnowItAll Informatics System offers a complete suite of tools for the computer-based prediction of a potential drug's ADME/Tox profile.
Tuesday, October 04, 2005
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.
Towards Patient-Specific Drug Screening
A new breakthrough by the 3D stem cell printing team at Heriot-Watt could pave the way to individually tailored drug testing regimes, both reducing the need for animal testing and ensuring that patients receive drugs which are most effective for their individual needs.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Gut Bacteria Can Dramatically Amplify Cancer Immunotherapy
Manipulating microbes maximizes tumor immunity in mice.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos